Targeted Therapeutics - From Chemical Structures to Diagnostic and Therapeutic AgentsARMBRUSTER, Christine.Current pharmaceutical design (Print). 2009, Vol 15, Num 2, issn 1381-6128, 126 p.Serial Issue

Targeted Drugs and Nanomedicine: Present and FutureDEBBAGE, Paul.Current pharmaceutical design (Print). 2009, Vol 15, Num 2, pp 153-172, issn 1381-6128, 20 p.Article

Targeted Therapies in Solid Tumours: Pinpointing the Tumour's Achilles HeelKORNEK, Gabriela; SELZER, Edgar.Current pharmaceutical design (Print). 2009, Vol 15, Num 2, pp 207-242, issn 1381-6128, 36 p.Article

Thrombosis of a drug-eluting stent after almost 2 years in an HIV-infected patientSTÖLLBERGER, Claudia; ARMBRUSTER, Christine; GMEINHART, Bernd et al.AIDS (London). 2007, Vol 21, Num 8, pp 1064-1065, issn 0269-9370, 2 p.Article

Immunoglobulin G Fcγ receptor expression on polymorphonuclear cells in bronchoalveolar lavage fluid of HIV-infected and HIV-seronegative patients with bacterial pneumoniaARMBRUSTER, Christine; KRUGLUGER, Walter; HUBER, Monika et al.Clinical chemistry and laboratory medicine. 2004, Vol 42, Num 2, pp 192-197, issn 1434-6621, 6 p.Article

Chemoenzymatic Synthesis of Small Molecule Human TherapeuticsNINGQING RAN; EUGENE RUI; JINHUA LIU et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 2, pp 134-152, issn 1381-6128, 19 p.Article

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12ARMBRUSTER, Christine; STIEGLER, Gabriela M; VCELAR, Brigitta A et al.Journal of antimicrobial chemotherapy (Print). 2004, Vol 54, Num 5, pp 915-920, issn 0305-7453, 6 p.Article

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1ARMBRUSTER, Christine; STIEGLER, Gabriela M; VCELAR, Brigitta A et al.AIDS (London). 2002, Vol 16, Num 2, pp 227-233, issn 0269-9370Article

A simple method to quantify staphylococcal protein A in the presence of human or animal IgG in various samplesSTEINDL, F; ARMBRUSTER, Christine; HAHN, R et al.Journal of immunological methods. 2000, Vol 235, Num 1-2, pp 61-69, issn 0022-1759Article

Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety dataVCELAR, Brigitta; STIEGLER, Gabriela; KATINGER, Hermann et al.AIDS (London). 2007, Vol 21, Num 16, pp 2161-2170, issn 0269-9370, 10 p.Article

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)JOOS, Beda; TRKOLA, Alexandra; KUSTER, Herbert et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 5, pp 1773-1779, issn 0066-4804, 7 p.Article

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluationSTIEGLER, Gabriela; ARMBRUSTER, Christine; VETTER, Norbert et al.AIDS (London). 2002, Vol 16, Num 15, pp 2019-2025, issn 0269-9370, 7 p.Article